Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - CONTRAFECT Corp | d789653dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): September 16, 2014
ContraFect Corporation
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-36577 | 39-2072586 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| 28 Wells Avenue, Third Floor Yonkers, New York |
10701 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (914) 207-2300
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01 | Other Events |
Trellis Bioscience, LLC (“Trellis”) received a $3.3 million Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases to fund pre-clinical studies of CONTRAFECT’S CF-404, the universal influenza treatment resulting from a collaboration between Trellis and ContraFect Corporation (the “Company”), and subsequently exclusively licensed to the Company. On August 14, 2014, the Company amended its exclusive license agreement with Trellis to establish the terms under which Trellis and the Company would conduct these pre-clinical studies. On September 16, 2014, the Company issued a press release announcing the grant award. A copy of the press release is filed as Exhibit 99.1 hereto, which is incorporated by reference into this item 8.01.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits.
| Exhibit |
Description | |
| 99.1 | Press release of the Company, dated September 16, 2014 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
| CONTRAFECT CORPORATION | ||||||||
| Date: September 18, 2014 | By: |
/s/ Julia P. Gregory | ||||||
| Name: | Julia P. Gregory | |||||||
| Title: | Chief Executive Officer | |||||||
EXHIBIT INDEX
| Exhibit |
Description | |
| 99.1 | Press release of the Company, dated September 16, 2014 | |